Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

2013980 citationsJournal Articlebronze Open Access

Authors

Dick de Zeeuw · University of Groningen

Tadao Akizawa · Showa University

Paul Audhya · Reata Pharmaceuticals (United States)

George L. Bakris · University of Chicago

Melanie Chin · Reata Pharmaceuticals (United States)

Heidi Christ‐Schmidt · Statistics Collaborative

Angie Goldsberry

Abstract

Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes. A higher rate of cardiovascular events with bardoxolone methyl than with placebo prompted termination of the trial. (Funded by Reata Pharmaceuticals; BEACON ClinicalTrials.gov number, NCT01351675.).

Topics & Keywords

Blood Pressure and Hypertension Studies Pharmacology and Obesity Treatment Eicosanoids and Hypertension Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 26, pp. 2492-2503

DOI: 10.1056/nejmoa1306033

Field-Weighted Citation Impact: 50.99